Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Roswell Park Researchers Evaluate Promising Drug For Intolerant Or Resistant CML
Roswell Park Cancer Institute (RPCI) scientists are investigating a promising drug for chronic myeloid leukemia (CML) patients who have become intolerant or resistant to standard therapies. Meir Wetzler, MD, Department of Medicine at Roswell Park Cancer Institute, analyzed the effectiveness of omacetaxine (OM) in an ongoing phase II clinical study and will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL.
generic viagra online
HIV/AIDS Groups Demonstrate At Capitol Rotunda, Call For Action On Domestic, Global Epidemics
Twenty-six people representing a coalition of five HIV/AIDS groups from Washington, D.C., Philadelphia and New York were arrested on Thursday for unlawfully demonstrating in the Capitol rotunda, the AP/Washington Post reports (7/9). According to Politico, the protestors were demanding "congressional action on three AIDS priorities: the end of the federal ban on syringe exchange, increased housing funding for [people living with AIDS] and significant increases in U.S. international AIDS contributions" (McGrane, 7/9). The group contends that the Obama "administration"s budget proposal "essentially flatlines global AIDS funding,"" CNN.com reports. In a statement, Omolola Adele-Oso of DC Fights Back, said, "HIV is not in recession. So why are we bailing out the bankers with $9 trillion, but breaking promises to fund life-saving AIDS programs in the U.S. and around the world at a fraction of that cost?" (7/9).
News of the day
For Doctors And Even Patients, Rationing Health Care Is An Everyday Occurrence
In an essay in The Washington Post, an infectious disease specialist writes that "the unspoken truth among doctors is that we objectively or subjectively ration care, and often don"t tell patients or their families." Organs, for example, "are a precious commodity, their donation strictly regulated by national guidelines. ò€¦ Because donors are scarce, it seems appropriate to ration their organs on the basis of need and other ethical and medical considerations." Medical care is also rationed through long wait times to see physicians (ranging from 11 to 50 days in major cities, according to a 2009 survey by Merritt Hawkins & Associates) or shortages of beds in a hospital.
Cardiovascular

Sinovac Provides Update On Clinical Trial For H1N1 Vaccine Trials

Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, the preliminary tests on the A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans. The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day safety observation period, none of the volunteers participating in Sinovac"s clinical tests exhibited any signs of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to seasonal influenza vaccine. The adverse events were all mild and transient. The most common symptom is pain at the site of injection. This clinical trial is organized by China"s Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying great attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical site to inspect the clinical study. In June 2009, Sinovac announced that the Ministry of Health had made an initial order of 4 million doses of Panflu, which is expected to be delivered by the end of September. As usual, Sinovac"s seasonal influenza vaccine has been released by China SFDA and officially launched to the market at the end of July 2009. About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac"s commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac"s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Sinovac Biotech Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009